A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes

• Published in: Cells (Basel, Switzerland) Vol. 9; no. 9; p. 1923
• Main Authors: Michel, Martin C, Michel-Reher, Martina B, Hein, Peter
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19.08.2020; MDPI
• Subjects: Adrenergic receptors; adrenoceptor; constitutive activity; drug development; Drug Development - methods; Drug Inverse Agonism; G proteins; Health aspects; Humans; inverse agonism; Inverse agonists; Kinases; Ligands; Proteins; Receptors, Adrenergic, beta-2 - therapeutic use; Review; Signal transduction; United States; drug development; adrenoceptor; constitutive activity; inverse agonism
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells9091923

As many, if not most, ligands at G protein-coupled receptor antagonists are inverse agonists, we systematically reviewed inverse agonism at the nine adrenoceptor subtypes. Except for β -adrenoceptors, inverse agonism has been reported for each of the adrenoceptor subtypes, most often for β -adrenoceptors, including endogenously expressed receptors in human tissues. As with other receptors, the detection and degree of inverse agonism depend on the cells and tissues under investigation, i.e., they are greatest when the model has a high intrinsic tone/constitutive activity for the response being studied. Accordingly, they may differ between parts of a tissue, for instance, atria vs. ventricles of the heart, and within a cell type, between cellular responses. The basal tone of endogenously expressed receptors is often low, leading to less consistent detection and a lesser extent of observed inverse agonism. Extent inverse agonism depends on specific molecular properties of a compound, but inverse agonism appears to be more common in certain chemical classes. While inverse agonism is a fascinating facet in attempts to mechanistically understand observed drug effects, we are skeptical whether an a priori definition of the extent of inverse agonism in the target product profile of a developmental candidate is a meaningful option in drug discovery and development.